A unique type of GSK-3 inhibitor brings new opportunities to the clinic

Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects

(2016) Florence F. Wagner et al.   ACS Chemical Biology

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

(2016) Mansi R. Khanna et al.   Alzheimers & Dementia

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging

(2016) Steven H. Liang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The contribution of astrocytes to Alzheimer's disease

(2014) Amy M. Birch   BIOCHEMICAL SOCIETY TRANSACTIONS

Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth

(2014) I Azoulay-Alfaguter et al.   ONCOGENE

Repetitive and Stereotypic Phenomena and Dementia

(2013) Gabriele Cipriani et al.   American Journal of Alzheimers Disease and Other Dementias

An Overview of Autophagy: Morphology, Mechanism, and Regulation

(2013) Katherine R. Parzych et al.   ANTIOXIDANTS & REDOX SIGNALING

Glycogen Synthase Kinase-3 Inhibitors Reverse Deficits in Long-term Potentiation and Cognition in Fragile X Mice

(2013) Aimee V. Franklin et al.   BIOLOGICAL PSYCHIATRY

Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3

(2013) E. Beurel et al.   JOURNAL OF IMMUNOLOGY

Tau pathology and neurodegeneration

(2013) Maria Grazia Spillantini et al.   LANCET NEUROLOGY

The role of autophagy in neurodegenerative disease

(2013) Ralph A Nixon   NATURE MEDICINE

Object recognition test in mice

(2013) Marianne Leger et al.   Nature Protocols

Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments

(2013) Margaret K. King et al.   PHARMACOLOGY & THERAPEUTICS

Inhibition of Glycogen Synthase Kinase-3 Ameliorates β-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model

(2012) Limor Avrahami et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes

(2012) Philip T.T. Ly et al.   JOURNAL OF CLINICAL INVESTIGATION

Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's Disease

(2012) D. E. Hurtado et al.   JOURNAL OF NEUROSCIENCE

Autophagy modulation as a potential therapeutic target for diverse diseases

(2012) David C. Rubinsztein et al.   NATURE REVIEWS DRUG DISCOVERY

Elucidating Substrate and Inhibitor Binding Sites on the Surface of GSK-3β and the Refinement of a Competitive Inhibitor

(2011) Avital Licht-Murava et al.   JOURNAL OF MOLECULAR BIOLOGY

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

(2011) Hagit Eldar-Finkelman et al.   Frontiers in Molecular Neuroscience

Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 Mutations

(2010) Ju-Hyun Lee et al.   CELL

Role of glycogen synthase kinase-3 in Alzheimer’s disease pathogenesis and glycogen synthase kinase-3 inhibitors

(2010) Jesús Avila et al.   Expert Review of Neurotherapeutics

The neurobiology of repetitive behavior: Of mice…

(2010) Marieke Langen et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process

(2010) Bart De Strooper   PHYSIOLOGICAL REVIEWS

GSK3 Influences Social Preference and Anxiety-Related Behaviors during Social Interaction in a Mouse Model of Fragile X Syndrome and Autism

(2010) Marjelo A. Mines et al.   PLoS One

Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo

(2010) Qing Zhu et al.   PROSTATE

Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndrome

(2009) Christopher J. Yuskaitis et al.   BIOCHEMICAL PHARMACOLOGY

The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal

(2009) John Hardy   JOURNAL OF NEUROCHEMISTRY

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

(2009) L. Serenó et al.   NEUROBIOLOGY OF DISEASE

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease

(2009) Diane P. Hanger et al.   TRENDS IN MOLECULAR MEDICINE

Abnormalities in brain structure and behavior in GSK-3alpha mutant mice

(2009) Oksana Kaidanovich-Beilin et al.   Molecular Brain

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics

(2008) Hanna Rosenmann et al.   EXPERIMENTAL NEUROLOGY